Short Interest in Nicox SA (OTCMKTS:NICXF) Rises By 1,904.8%

Nicox SA (OTCMKTS:NICXF) was the recipient of a significant growth in short interest in March. As of March 13th, there was short interest totaling 421 shares, a growth of 1,904.8% from the February 26th total of 21 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days. Currently, 0.0% of the shares of the company are sold short. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ∞ days.

Nicox Stock Performance

NICXF stock opened at $0.30 on Wednesday. Nicox has a one year low of $0.25 and a one year high of $0.30. The firm’s fifty day moving average is $0.30 and its 200 day moving average is $0.30.

About Nicox

Nicox is a global biopharmaceutical company focused on the research, development and commercialization of innovative treatments for eye diseases. The company’s therapeutic approach centers on nitric oxide–donating compounds and anti-inflammatory agents designed to address glaucoma, ocular surface disorders and allergic eye conditions. With a pipeline spanning pre-clinical to late-stage clinical programs, Nicox aims to bring new modalities to market that target unmet needs in ophthalmology.

The company’s lead commercial product, ZERVIATE® (ciclesonide ophthalmic solution), is indicated for the relief of ocular itching associated with allergic conjunctivitis.